KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
57 hedge funds and large institutions have $261M invested in KalVista Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 8 closing their positions.
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
19% more funds holding
Funds holding: 48 → 57 (+9)
4.16% more ownership
Funds ownership: 73.12% → 77.28% (+4.2%)
6% less capital invested
Capital invested by funds: $278M → $261M (-$16.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.93M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$5.56M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$4.02M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
+$2.76M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.16M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.42M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.05M |
| 4 |
Millennium Management
New York
|
-$1.15M |
| 5 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$629K |
KALV Hedge Fund Activity: Q4 2018 in Review
57 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2018, worth a combined $261M — down 5.9% from $278M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 8 closed out — a net gain of 9 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.93M. The largest seller was BVF Inc, cutting an estimated $7.16M.
- 57 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2018, up from 48 in Q3 2018.
- Funds reported $261M of KalVista Pharmaceuticals stock for Q4 2018, down 5.9% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of +9 holders.
- The largest KalVista Pharmaceuticals buyer in Q4 2018 was Adage Capital Partners, an estimated $5.93M added.
- The largest KalVista Pharmaceuticals seller in Q4 2018 was BVF Inc, an estimated $7.16M sold.
Based on aggregated 13F filings for Q4 2018.